ArticleFrontiers in immunology2019
Lung Surfactant Lipids Provide Immune Protection Against
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Protocols in the therapeutic use of medical ozone: a matter of debate.Medical gas research · 2026Article
- Viral-associated septic shock in pediatric pneumonia: a retrospective analysis of pathogen-specific risks and comparative clinical features with bacterial sepsis.Frontiers in pediatrics · 2025Article
- Exploring the influence of anionic lipids in the host cell membrane on viral fusion.Biochemical Society transactions · 2024Review
- RSV enhancesInfection and immunity · 2024Article
- The Metabolic Potential of the Human Lung Microbiome.Microorganisms · 2024Article
- Identification of genetic biomarkers, drug targets and agents for respiratory diseases utilising integrated bioinformatics approaches.Scientific reports · 2023Article
- The Relationship of Cholesterol Responses to Mitochondrial Dysfunction and Lung Inflammation in Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2023Review
- TACSTD2 upregulation is an early reaction to lung infection.Scientific reports · 2022Article
- Non-Cellular Layers of the Respiratory Tract: Protection against Pathogens and Target for Drug Delivery.Pharmaceutics · 2022Review
- Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.Current drug metabolism · 2022Article
- Cooperative action of SP-A and its trimeric recombinant fragment with polymyxins against Gram-negative respiratory bacteria.Frontiers in immunology · 2022Article
- Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- The Role of ABC Transporters in Lipid Metabolism and the Comorbid Course of Chronic Obstructive Pulmonary Disease and Atherosclerosis.International journal of molecular sciences · 2021Review
- The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course.Biochemistry (Moscow) Supplement. Series A, Membrane and cell biology · 2021Article
- Lipid-Protein and Protein-Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis.International journal of molecular sciences · 2020Review
- Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways.Frontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-typeable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.